YOLFTbeta
AgomAb Therapeutics NV American Depositary Shares

AgomAb Therapeutics NV American Depositary Shares

AGMB · NASDAQ · Healthcare / Biotechnology

6.36USD+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close6.36
Open6.32
Day Range5.73 – 6.61
52-Week Range8.75 – 17.82
Volume192.64K
Market Cap521.04M
P/E (TTM)0.00
Forward P/E0.00
EPS-1.53
Dividend Yield0.00%
50-Day Avg13.17
200-Day Avg12.62

About

AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials. It also develops AGMB-101, a HGF-mimetic monoclonal antibody that acts through agonism or stimulation of the MET receptor and has demonstrated antifibrotic and regenerative activity in preclinical models. The company was incorporated in 2017 and is headquartered in Antwerp, Belgium.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Tim Knotnerus MSc, Ph.D.
  • Employees62
  • HeadquartersPosthoflei 1/6, Antwerp, Belgium, 2600, USA
  • Websitehttps://www.agomab.com

Leadership

  • Dr. Tim Knotnerus MSc, Ph.D.CEO & Executive Director · b. 1983
  • Mr. Paolo Michieli Ph.D.Founder, Senior Advisor & Member of Scientific Advisory Board
  • Mr. Pierre Kemula B.Sc.Chief Financial Officer · b. 1974
  • Sofie Van GijselVice President of Investor Relations
  • Ms. Ellen LefeverGeneral Counsel · b. 1985
  • Dr. Philippe Wiesel M.D.Chief Medical Officer · b. 1967
  • Dr. Paul Van Der Horst Ph.D.Chief Business Officer · b. 1988
  • Dr. Andrea Sáez Borderías Ph.D.Chief Development Officer · b. 1982

Financials

Income Statement

Currency: EUR2022-12-312023-12-312024-12-312025-12-31
Total Revenue0000
Cost of Revenue---210.36K
Gross Profit----210.36K
Operating Expense---59.06M
Operating Income-22.63M-31.19M-48.02M-59.27M
EBITDA-10.74M-11.88M-45.88M-62.27M
Net Income-8.14M-11.39M-46.27M-62.55M
R&D19.42M26.31M39.31M48.88M
Interest Expense45.00K31.00K67.00K60.00K

Balance Sheet

Currency: EUR2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets84.00M101.00M171.26M206.36M153.71M
Total Liabilities41.63M34.75M19.82M18.28M22.80M
Total Equity42.36M66.25M151.44M188.08M130.90M
Cash53.59M27.67M122.40M171.46M86.42M
Total Debt----1.25M
Net Debt-----85.16M

Cash Flow

Currency: EUR2022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-18.97M-24.59M-46.83M-51.74M
Investing Cash Flow----33.00M
Financing Cash Flow37.63M79.32M96.76M-338.00K
Capital Expenditure00675.00K4.00K
Free Cash Flow-18.97M-24.59M-47.50M-51.74M
FCF to OCF100.00%100.00%101.44%100.01%

Earnings

Report DateDec 31, 2025Apr 24, 2026Jun 30, 2026
EPS Estimate-41.04-0.45-0.45
EPS Actual--0.42-
Surprise-7.85%-
Timing---

Key Statistics & Ratios

Market Cap521.04M
Enterprise Value236.85M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book1.72
EPS-1.53
Book Value2.58
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-65.56M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-39.22%
Return on Assets-20.58%
Shares Outstanding49.25M
Shares Float11.45M
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Ownership Breakdown

Institutions
53.64%
Insiders
5.90%
Retail / Other
40.46%

Top Institutional Holders

  • EQT Fund Management S.à r.l.
    5.14M10.44%
  • Sanofi
    2.78M5.65%
  • Redmile Group, LLC
    2.73M5.55%
  • Cormorant Asset Management, LLC
    2.47M5.01%
  • TCG Crossover Management, LLC
    2.05M4.17%
  • Federated Hermes Inc
    1.62M3.29%
  • Casdin Capital, LLC
    1.55M3.15%
  • Andera Partners
    1.54M3.12%
  • FMR Inc
    1.46M2.96%
  • Nantahala Capital Management, LLC
    1.20M2.44%
  • Aberdeen Group PLC
    846.70K1.72%
  • Samsara BioCapital, LLC
    600.00K1.22%
  • Perceptive Advisors LLC
    600.00K1.22%
  • Siren, L.L.C.
    411.25K0.84%

Top Fund Holders

  • Federated Hermes Kaufmann R
    981.18K1.99%
  • Federated Hermes Kaufmann Small Cap A
    615.71K1.25%
  • Fidelity Growth Company Fund
    507.25K1.03%
  • abrdn Healthcare Investors
    463.27K0.94%
  • abrdn Life Sciences Investors
    329.62K0.67%
  • abrdn World Healthcare
    312.73K0.64%